BioSpace News Archive

Livoletide did not achieve statistically significant improvement in primary endpoint of change in hyperphagia and food-related behaviors relative to placebo –

LFB Announces FDA Approval of SEVENFACT ® , a New Recombinant Coagulation Factor VIIa, for the Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors LES ULIS, France--( BUSINESS WIRE )-- LFB today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) 2061 for SEVENFACT®, a new recombinant coagulation Factor VIIa [coagulation factor VIIa (recombinant)-jncw], for the treatment and con

Increased access to rapid testing will help local communities manage spread of the virus

Annual Meeting to be webcast in virtual-only format

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it has submitted an Investigational New Drug (IND) amendment with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1b/2a clinical trial of its lead program, HST 001 for the treatment of androgenic alopecia in men.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, provided a corporate update in response to the COVID-19 pandemic.

Immunomedics Conference call and webcast today at 8:00 a.m. Eastern Time

Cigna Corporation (NYSE:CI) announced today that, due to the public health impact of COVID-19, the company will hold its 2020 Annual Meeting of Shareholders in a virtual meeting format only, via audio webcast.

Janssen Pharmaceutical has published comprehensive data from studies evaluating the safety of Tremfya

Hope Biosciences, today announced that FDA has approved a Phase II clinical trial evaluating efficacy and safety of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COV